Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (PRCT) delivers pioneering surgical robotics solutions for urologic care, with its AquaBeam and HYDROS systems redefining minimally invasive BPH treatment. This news hub provides investors and medical professionals with essential updates on PRCT's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative updates including FDA clearances, peer-reviewed study results, and financial performance reports. Our curated collection features official press releases on product innovations, partnership announcements, and clinical trial outcomes backed by PRCT's extensive clinical evidence base.
Stay informed about developments in aquablation therapy technology, global market expansion efforts, and advancements in AI-driven surgical planning. Content spans regulatory filings, executive leadership updates, and analyses of PRCT's growing body of clinical validation across urologic applications.
Bookmark this page for streamlined access to PROCEPT BioRobotics' latest achievements in surgical robotics. Check regularly for verified updates on technologies improving patient outcomes through precision tissue resection and image-guided procedures.
PROCEPT BioRobotics announced the American Medical Association (AMA) has granted a new CPT Category I code for its Aquablation therapy, used to treat benign prostatic hyperplasia (BPH). This decision, driven by increased usage and clinical success, will take effect on January 1, 2026, replacing the current Category III CPT code. Until then, the existing code, 0421T, remains in use. This advancement underscores Aquablation therapy's safety, efficacy, and acceptance in treating BPH.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology, will present at the 2024 Truist Securities MedTech Conference in Boston, Massachusetts. The presentation is scheduled for June 18, 2024, at 1:20 p.m. Eastern Time. Management will provide insights into the company's advancements and strategies. Investors can access the live webcast and archived recordings on the company's investor relations website.
PROCEPT BioRobotics (Nasdaq: PRCT), a leader in surgical robotics focused on urology, announces participation in two key conferences: the 2024 Leerink Partners Healthcare Crossroads Conference on May 29 in Austin, Texas, and the 44th Annual William Blair Growth Stock Conference on June 4 in Chicago. Management will present at 10:20 a.m. ET and 5:00 p.m. ET respectively. Both presentations will be available via live webcast and archived for 90 days on the company's investor relations website.
PROCEPT BioRobotics presented long-term real-world data at the 2024 AUA Annual Meeting demonstrating the sustained benefits of Aquablation therapy for men with benign prostatic hyperplasia (BPH). The data showcased the efficacy of Aquablation therapy in treating BPH, emphasizing safety, durability, and positive outcomes such as improved International Prostate Symptom Score (IPSS) and increased peak urinary flow rate (Qmax). The results from various studies highlighted the potential for Aquablation therapy to become the new standard of care in BPH management.
PROCEPT BioRobotics reported total revenue of $44.5 million for the first quarter of 2024, marking an 83% increase from the previous year. The company's U.S. revenue saw significant growth across various segments, with handpiece and consumables revenue increasing by 101%. The company sold 38 U.S. robotic systems during the quarter and increased its international revenue by 65% compared to the prior year period. PROCEPT adjusted its fiscal year 2024 total revenue guidance to $213.5 million, showcasing a strong start to the year and optimistic growth projections.
PROCEPT BioRobotics presented a late-breaking post-market survey at the Japanese Urological Association Annual Meeting on positive Aquablation therapy outcomes for men in Japan with lower urinary tract symptoms due to benign prostatic hyperplasia. The data showcased the safety and effectiveness of Aquablation therapy in treating men with BPH, highlighting reproducible results and supporting a paradigm shift in the surgical treatment of the condition.
Key highlights from the data include treating 103 men with mean age and baseline IPSS of 71 ± 7 and 18 ± 9, respectively, with a mean prostate volume of 82 ml. The data showed significant improvements in IPSS and quality-of-life scores, with no reports of pad-use incontinence or serious device-related adverse events. The results demonstrate the exceptional safety and efficacy of Aquablation therapy in Japanese men with BPH.
FAQ
What is the current stock price of Procept Biorobotics (PRCT)?
What is the market cap of Procept Biorobotics (PRCT)?
